Please amend the claims pursuant to 37 C.F.R. 1.21 as follows (see Appendix 1, which contains a "marked up" version pursuant to 1.121).

Kindly substitute the following claims 1, 3 and 21 for pending claims 1, 3, and 21:

1. (Amended) A compound of the formula



wherein

each of Ar and Ar′ is independently chosen from a group consisting of phenyl and pyridyl each optionally substituted by one or more members from the group consisting of alkyl, alkoxy, cyano, nitro, amino, alkylsulfonylamino, or alkylamino;

Y is chosen from the group consisting of a nitrogen atom, a CH, C-OH, C-CN, or a C-$CONH_2$ group;

R is a hydrogen atom or a lower alkyl group;

B is phenyl, optionally substituted by one or more members selected from the group consisting of alkyl, alkoxy, halogen, cyano, nitro, amino, alkylsulfonylamino, and alkylamino; wherein when the phenyl ring is substituted with two members of the group, the substituents may be connected together to form a ring fused to the phenyl with the provisos that

1) when B is methoxyphenyl and Y is any of C-CN, and C-$CONH_2$ then Ar and Ar′ are not simultaneously unsubstituted phenyl;

2) when Y equal CH, Ar and Ar' cannot both be optionally substituted pyridyl;

3) when Y equal CH and one of Ar and Ar' equal optionally substituted phenyl, the other of Ar' and Ar cannot equal optionally substituted pyridyl; and

4) when Y = CH and each of Ar and Ar' are optionally substituted phenyl wherein said substitution is methyl, then B cannot be unsubstituted phenyl,

and enantiomers, diastereomers, N-oxides crystalline forms, hydrates and pharmaceutically acceptable salts thereof.

3. (Amended) A compound of claim 1 selected from the group consisting of:

1-(3,3-diphenylpropyl)-4-(2-methoxyphenyl)piperazine;

1-(3,3-diphenylpropyl)-4-[5-(2,3-dihydro-1,4-benzodioxinyl)]piperazine;

1-[3,3-*bis*-(4-nitrophenyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[3,3-*bis*-(4-methoxyphenyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[*N-N-bis*-(2-pyridyl)-2-aminoethyl]-4-(2-methoxyphenyl)piperazine;

1-[3-aminocarbonyl-3-phenyl-3-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[3-cyano-3-(2-nitrophenyl)-3-phenylpropyl]-4-(2-methoxyphenyl)piperazine;

1-[3-aminocarbonyl-3-(2-nitrophenyl)-3-phenylpropyl]-4-(2-methoxyphenyl)piperazine;

1-[3-cyano-3-(2-nitrophenyl)-3-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[3-aminocarbonyl-3-(2-nitrophenyl)-3-(2-pyridyl)propyl]-4-(2-methoxyphenyl)-piperazine;

and enantiomers, N-oxides, hydrates, and pharmaceutically acceptable salts thereof.

21. (Amended) A compound selected from the group consisting of

1-[3,3-bis-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[3-hydroxy-3,3-bis-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-(4-1H-indolyl)-4-[3,3-bis-(2-pyridyl)propyl]piperazine;

1-[3-cyano-3,3-bis-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine;

1-[3-cyano-3-phenyl-3-(2-pyridyl)propyl]-4-(2-methoxyphenyl)piperazine; and

1-[N-(2-nitrophenyl)-N-(2-pyridyl)-2-aminoethyl]-4-(2-methoxyphenyl)piperazine.